Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 11, 2016
Reporting Period: Second Quarter ended March 31, 2016
This filing serves as a notification that the company issued a press release on August 11, 2016, announcing its financial results for the quarter ended March 31, 2016. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover document (Form 8-K) and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only indicates that such information is contained within the referenced press release.
Guidance, Outlook, and Risks
Management Commentary: The company announced a conference call to discuss the financial results.
Legal Disclaimer: In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liability of that section. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 11, 2016) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the conference call mentioned in the announcement.
- Confirm the status of the company's clinical pipeline and regulatory milestones, as these are typically the primary drivers for biotech firms like Aclaris.
- Check subsequent filings for any updates to the financial results announced in this report.